August 15th 2025
The UC Davis team is studying a less invasive way of delivering gene therapy to the eye: injecting the gene therapy into the suprachoroidal space, a tiny layer between the white of the eye and the blood vessels that feed the retina.
Two New Therapies for Dry Eye Will Soon be on the Market
June 9th 2023The FDA has approved two novel therapies for patients with dry eye disease: Vevye (previously CyclASol) is a water-free, preservative-free solution, and Miebo, which address the excessive tear evaporation that is seen with dry eye.
Read More
University of Virginia Researchers Discover New Target to Prevent Vision Loss
March 24th 2023The discovery of a protein that determines levels of vascular endothelial growth factor-A (VEGF) could lead to new therapies for macular degeneration, diabetic retinopathy and other common causes of vision loss.
Read More
Eyelea is Shown to Be More Effective Than Avastin at Weaning nvAMD Patients off Treatments
December 8th 2022The early response to neovascular age-related macular degeneration (nvAMD) treatment with aflibercept (Eyelea) was much greater than the response to bevacizumab (Avastin), in hopes of weaning those affected off the therapies sooner.
Read More